Dr. Kelly L. Vallance | Hematology ...

Dr. Kelly L. Vallance

Claim this profile

Cook Children's Medical Center

Expert in Cancer
Expert in Brain Tumor
20 reported clinical trials
35 drugs studied

About Kelly L. Vallance

Education:

  • Earned a Medical degree (MD).

Experience:

  • Serves as the primary investigator for oncology research studies at Cook Children's Medical Center.
  • Specializes in pediatric oncology, focusing on Wilms tumors, a type of kidney cancer in children.
  • Actively engaged in advancing treatments for childhood cancers through clinical research.

Area of expertise

1Cancer
Global Leader
Kelly L. Vallance has run 15 trials for Cancer. Some of their research focus areas include:
Stage I
Stage IV
Stage II
2Brain Tumor
Global Leader
Kelly L. Vallance has run 13 trials for Brain Tumor. Some of their research focus areas include:
Stage I
Stage II
MTOR positive

Affiliated Hospitals

Image of trial facility.
Cook Children's Medical Center

Clinical Trials Kelly L. Vallance is currently running

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Image of trial facility.

Chemotherapy

for Wilms Tumor

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting1 award Phase 212 criteria

More about Kelly L. Vallance

Clinical Trial Related8 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Kelly L. Vallance has experience with
  • Cyclophosphamide
  • Carboplatin
  • Etoposide
  • Larotrectinib
  • Palbociclib
  • Erdafitinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Kelly L. Vallance specialize in?
Is Kelly L. Vallance currently recruiting for clinical trials?
Are there any treatments that Kelly L. Vallance has studied deeply?
What is the best way to schedule an appointment with Kelly L. Vallance?
What is the office address of Kelly L. Vallance?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security